Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial

HIV / AIDS

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

Clin Infect Dis.

Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT, Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team .

doi: 10.1093/cid/ciy913.

HIV / AIDS

Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

AIDS.

Mocroft A, Ryom L, Oprea C, Li Q, Rauch A, Boesecke C, Uzdaviniene V, Sedlacek D, Llibre JM, Lacombe K, Nielsen LN, Florence E, Aho I, Chkhartishvili N, Szlavik J, Dragovic G, Leen C, Sambatakou H, Staub T, Laguno M, Elinav H, Tomažič J, Peters L, EuroSIDA study group.

doi: 10.1097/QAD.0000000000002570.

HIV / AIDSViral Infections, Non-HIV

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Lancet Infect Dis.

Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL

doi: 10.1016/

Viral Infections, Non-HIV

Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review

J Viral Hepat.

Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt , Negro F

doi: 10.1111/jvh.12891.

Viral Infections, Non-HIV

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Lancet Infect Dis.

Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ

doi: 10.1016/

HIV / AIDS

Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with HIV-1 and hepatitis C virus co-infection: AIDS Clinical Trials Group Sub-Study A5334s

Br J Clin Pharmacol.

Venuto CS, Cramer YS, Rosenkranz SL, Sulkowski M, Wyles DL, Cohen DE, Schmidt J, Alston-Smith BL, Morse GD

doi: 10.1111/bcp.14148.

Viral Infections, Non-HIV

Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study

Clin Infect Dis.

Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J

doi: 10.1093/cid/ciz633.

Viral Infections, Non-HIV

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030

Swiss Med Wkly.

Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos R, Lavanchy D, Müllhaupt B, Rauch A, Razavi H, Schmid P, Semela D, Stoeckle M, Negro F

doi: 10.4414/smw.2017.14543.

HIV / AIDSViral Infections, Non-HIV

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population

Hepatology.

Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S

doi: 10.1002/hep.29642.

Related content

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with HIV-1 and hepatitis C virus co-infection: AIDS Clinical Trials Group Sub-Study A5334s

Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study

Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population